Lupin Limited is one of the world’s leading pharmaceutical companies, driven by science and inspired by patients. Founded in 1968 by visionary leader Dr. Desh Bandhu Gupta, Lupin has grown from a modest start into a global healthcare powerhouse, trusted for its innovation, quality, and commitment to making healthcare accessible worldwide. Headquartered in Mumbai, Lupin operates across the U.S., LATAM, APAC, EMEA, and India, with its products reaching more than 100 markets globally.
With a robust portfolio of over 1,200 products, Lupin is recognized for its diverse offerings in generics, branded generics, complex generics, APIs, biosimilars, and specialty medicines. The company’s leadership in key therapeutic areas—such as respiratory, cardiovascular, diabetes, gastrointestinal, women’s health, central nervous system, and anti-infectives—reflects its dedication to addressing the most pressing health needs of communities worldwide.
Lupin has established a strong global manufacturing and research presence, with 15 state-of-the-art manufacturing facilities and 7 advanced research centers supported by a highly skilled workforce of more than 22,000 professionals. The company’s focus on R&D, innovation, and digital transformation has enabled it to consistently deliver excellence and remain at the forefront of the pharmaceutical industry.
At its core, Lupin is deeply committed to patient-centricity and quality healthcare. The company’s mission goes beyond delivering affordable medicines—it is about creating meaningful health outcomes that make a real difference. Through Lupin Diagnostics, Lupin Digital Health, and Atharv Ability, the organization continues to expand its impact by offering comprehensive healthcare solutions tailored to evolving patient needs.
Innovation is at the heart of Lupin’s strategy. By developing complex generics, specialty medicines, and biosimilars, Lupin has carved a niche in highly competitive markets. Its focus on advanced drug delivery systems, sustainable practices, and next-generation therapies reflects its commitment to being a leader in pharmaceutical science and technology.
Beyond healthcare, Lupin actively contributes to the betterment of society through the Lupin Human Welfare and Research Foundation (LHWRF). Operating across more than 4,700 villages in eight Indian states, the foundation has positively transformed the lives of over 1.57 million people, focusing on improving livelihoods, education, healthcare access, and community development.
On the global stage, Lupin is a recognized leader in sustainability and ESG practices. Ranked in the top 5 percent worldwide in ESG performance with a DJSI score of 69, Lupin continues to set new benchmarks in environmental responsibility, ethical governance, and community engagement.
Lupin’s credibility is reinforced by its strong compliance with international regulatory standards and its consistent record of delivering safe, effective, and affordable medicines. Its success lies in balancing innovation with accessibility, ensuring that patients across developed and emerging markets can rely on its products.
Looking ahead, Lupin remains committed to expanding its global reach, leveraging digital health technologies, and driving transformative changes in the pharmaceutical landscape. With a foundation built on science, compassion, and responsibility, Lupin Limited continues to live its vision of enriching lives, empowering communities, and shaping a healthier future.
Share on